Difference between revisions of "Team:UCSC/Acetaminophen"
Brittneywick (Talk | contribs) |
Evan pepper (Talk | contribs) |
||
| (81 intermediate revisions by 3 users not shown) | |||
| Line 8: | Line 8: | ||
margin: auto; | margin: auto; | ||
background: honeydew; | background: honeydew; | ||
| − | width: | + | width: 100%; |
} | } | ||
h1 { | h1 { | ||
| − | font-family: | + | font-family: 'objektiv-mk1'!important; |
| + | font-size: 300%; /*!important*/ | ||
font-weight: 300 !important; | font-weight: 300 !important; | ||
| − | font-size: | + | width: 90%; |
| + | } | ||
| + | |||
| + | h2 { | ||
| + | font-family: 'objektiv-mk1' !important; | ||
| + | font-size: 200%; | ||
| + | font-weight: 300; | ||
| + | } | ||
| + | |||
| + | h3 { | ||
| + | font-family: 'objektiv-mk1' !important; | ||
| + | font-size: 120%; | ||
| + | font-weight: 400 !important; | ||
} | } | ||
| Line 23: | Line 36: | ||
.proj-button { | .proj-button { | ||
position: relative; | position: relative; | ||
| − | width: | + | width: 25%; |
| + | text-decoration: none !important; | ||
} | } | ||
| Line 29: | Line 43: | ||
opacity: 1; | opacity: 1; | ||
display: inline-block; | display: inline-block; | ||
| − | width: | + | width: 30%; |
| + | height: auto; | ||
| + | transition: .5s ease; | ||
| + | backface-visibility: hidden; | ||
| + | } | ||
| + | |||
| + | .proj-button-image-solo { | ||
| + | opacity: 1; | ||
| + | display: inline-block; | ||
| + | width: 65%; | ||
height: auto; | height: auto; | ||
transition: .5s ease; | transition: .5s ease; | ||
| Line 44: | Line 67: | ||
transform: translate(-50%, -50%); | transform: translate(-50%, -50%); | ||
-ms-transform: translate(-50%, -50%) | -ms-transform: translate(-50%, -50%) | ||
| + | } | ||
| + | |||
| + | .overlap-button-text { | ||
| + | background-color: transparent; | ||
| + | color: black; | ||
| + | font-size: 20px; | ||
| + | font-family: "Objektiv-mk1" !important; | ||
| + | font-weight: 400 !important; | ||
| + | padding: 16px 32px; | ||
} | } | ||
.proj-button:hover .proj-button-image { | .proj-button:hover .proj-button-image { | ||
| − | opacity: 0. | + | opacity: 0.2; |
| + | } | ||
| + | |||
| + | .proj-button:hover .proj-button-image-solo { | ||
| + | opacity: 0.2; | ||
} | } | ||
.proj-button:hover .proj-button-desc { | .proj-button:hover .proj-button-desc { | ||
| − | opacity: 0. | + | opacity: 0.8; |
| + | } | ||
| + | |||
| + | .overlap-button-text { | ||
| + | background-color: transparent; | ||
| + | color: black; | ||
| + | font-size: 20px; | ||
| + | font-family: "Objektiv-mk1" !important; | ||
| + | font-weight: 400 !important; | ||
| + | padding: 16px 32px; | ||
} | } | ||
| Line 62: | Line 107: | ||
.paragraph-left { | .paragraph-left { | ||
| − | font-family: ' | + | font-family: 'objektiv-mk1' !important; |
font-size: 18px; | font-size: 18px; | ||
text-align: left; | text-align: left; | ||
| Line 69: | Line 114: | ||
p { | p { | ||
| − | font-family: ' | + | font-family: 'objektiv-mk1' !important; |
/* margin-left: 200px !important; | /* margin-left: 200px !important; | ||
margin-right: 200px !important;*/ | margin-right: 200px !important;*/ | ||
| Line 76: | Line 121: | ||
.firstword { | .firstword { | ||
| − | font-family: ' | + | font-family: 'objektiv-mk1' !important; |
| − | font-size: | + | font-size: 65px; |
} | } | ||
.quote { | .quote { | ||
| − | font-family: ' | + | font-family: 'objektiv-mk1' !important; |
font-style: italic !important; | font-style: italic !important; | ||
| − | font-size: | + | font-size: 28px; |
| + | line-height: 130%; | ||
} | } | ||
.quote-person { | .quote-person { | ||
| − | font-family: ' | + | font-family: 'objektiv-mk1' !important; |
| − | font-size: | + | font-size: 22px; |
width: 100% !important; | width: 100% !important; | ||
text-align: right !important; | text-align: right !important; | ||
| Line 94: | Line 140: | ||
.titleimg { | .titleimg { | ||
| − | + | vertical-align: middle; | |
| + | width: 25%; | ||
} | } | ||
| Line 102: | Line 149: | ||
.reference-list { | .reference-list { | ||
| − | font-family: ' | + | font-family: 'objektiv-mk1'; |
font-size: 12px; | font-size: 12px; | ||
text-align: left; | text-align: left; | ||
| Line 111: | Line 158: | ||
.reference-italic { | .reference-italic { | ||
| − | font-family: ' | + | font-family: 'objektiv-mk1'; |
font-size: 12px; | font-size: 12px; | ||
font-style: italic; | font-style: italic; | ||
| Line 117: | Line 164: | ||
figcaption { | figcaption { | ||
| − | font-family: ' | + | font-family: 'objektiv-mk1'; |
font-style: italic; | font-style: italic; | ||
font-size: 13px; | font-size: 13px; | ||
| Line 125: | Line 172: | ||
@media (min-width: 1144px) { | @media (min-width: 1144px) { | ||
.container { | .container { | ||
| − | + | width: 100% !important; | |
| − | + | } | |
| − | + | ||
| − | + | .text-container { | |
| − | + | width: 70%; | |
| − | + | padding-left: 15px; | |
| − | + | padding-right: 15px; | |
| − | + | } | |
| − | + | ||
| − | + | .titlebox { | |
| − | + | width: 80%; | |
| − | + | } | |
| − | + | ||
| + | figcaption { | ||
| + | font-size: 16px; | ||
| + | } | ||
} | } | ||
| Line 147: | Line 197: | ||
p { | p { | ||
| − | font-family: ' | + | font-family: 'objektiv-mk1' !important; |
margin-left: 10px !important; | margin-left: 10px !important; | ||
margin-right: 10px !important; | margin-right: 10px !important; | ||
| Line 154: | Line 204: | ||
.quote { | .quote { | ||
| − | font-family: ' | + | font-family: 'objektiv-mk1' !important; |
font-style: italic !important; | font-style: italic !important; | ||
| − | font-size: | + | font-size: 26px; |
} | } | ||
.quote-person { | .quote-person { | ||
| − | font-family: ' | + | font-family: 'objektiv-mk1' !important; |
| − | font-size: | + | font-size: 20px; |
width: 100%; | width: 100%; | ||
text-align: right; | text-align: right; | ||
| Line 190: | Line 240: | ||
} | } | ||
| − | @media (max-width: | + | @media (max-width: 992px) { |
| − | .proj-button-image { | + | .proj-button-image-solo { |
opacity: 1; | opacity: 1; | ||
display: inline-block; | display: inline-block; | ||
| − | width: | + | width: 30%; |
height: auto; | height: auto; | ||
transition: .5s ease; | transition: .5s ease; | ||
backface-visibility: hidden; | backface-visibility: hidden; | ||
} | } | ||
| + | } | ||
| − | + | @media (max-width: 768px) { | |
| − | + | .proj-button-image { | |
| − | + | opacity: 1; | |
| − | + | display: inline-block; | |
| − | + | width: 32%; | |
| − | + | height: auto; | |
| − | + | transition: .5s ease; | |
| − | + | backface-visibility: hidden; | |
| − | + | } | |
| − | + | .proj-button-image-solo { | |
| − | + | opacity: 1; | |
| − | + | display: inline-block; | |
| − | + | width: 35%; | |
| − | + | height: auto; | |
| + | transition: .5s ease; | ||
| + | backface-visibility: hidden; | ||
| + | } | ||
| − | + | .proj-button-desc { | |
| − | + | transition: .5s ease; | |
| + | opacity: 1; | ||
| + | position: absolute; | ||
| + | top: 100%; | ||
| + | left: 50%; | ||
| + | transform: translate(-50%, -50%); | ||
| + | -ms-transform: translate(-50%, -50%) | ||
| + | } | ||
| − | + | .overlap-button-text { | |
| + | background-color: rgba(94, 94, 94, 0.4); | ||
| + | border-radius: 60px; | ||
| + | color: white; | ||
} | } | ||
| + | |||
| + | h1 { | ||
| + | font-family: 'objektiv-mk1'; /*!important*/ | ||
| + | font-size: 220%; /*!important*/ | ||
| + | width: 80%; | ||
| + | } | ||
| + | |||
| + | h2 { | ||
| + | font-family: 'objektiv-mk1'; /*!important*/ | ||
| + | font-size: 20px; /*!important*/ | ||
| + | } | ||
.quote { | .quote { | ||
| − | font-family: ' | + | font-family: 'objektiv-mk1' !important; |
font-style: italic !important; | font-style: italic !important; | ||
font-size: 20px; | font-size: 20px; | ||
| Line 230: | Line 305: | ||
.quote-person { | .quote-person { | ||
width: 100%; | width: 100%; | ||
| − | font-family: ' | + | font-family: 'objektiv-mk1' !important; |
font-size: 16px; | font-size: 16px; | ||
text-align: right !important; | text-align: right !important; | ||
| Line 243: | Line 318: | ||
figcaption { | figcaption { | ||
| − | font-size: | + | font-size: 14px; |
| − | line-height: | + | line-height: 140%; |
| + | } | ||
| + | |||
| + | .reference-list { | ||
| + | font-family: 'objektiv-mk1'; | ||
| + | font-size: 12px; | ||
| + | text-align: left; | ||
| + | list-style-type: none; | ||
| + | line-height: 100%; | ||
| + | margin-bottom: 80px; | ||
| + | margin-right: -70px; | ||
| + | margin-left: -70px; | ||
} | } | ||
} | } | ||
| Line 255: | Line 341: | ||
@media (max-width: 576px) { | @media (max-width: 576px) { | ||
.proj-button-image { | .proj-button-image { | ||
| − | + | opacity: 1; | |
| − | + | display: inline-block; | |
| − | + | width: 50%; | |
| − | + | height: auto; | |
| − | + | transition: .5s ease; | |
| − | + | backface-visibility: hidden; | |
| − | + | } | |
| − | + | .proj-button-image-solo { | |
| − | + | opacity: 1; | |
| − | + | display: inline-block; | |
| − | + | width: 50%; | |
| − | + | height: auto; | |
| − | + | transition: .5s ease; | |
| − | + | backface-visibility: hidden; | |
| − | + | } | |
| + | |||
| + | .proj-button-desc { | ||
| + | transition: .5s ease; | ||
| + | opacity: 1; | ||
| + | position: absolute; | ||
| + | top: 100%; | ||
| + | left: 50%; | ||
| + | transform: translate(-50%, -50%); | ||
| + | -ms-transform: translate(-50%, -50%) | ||
| + | } | ||
| + | |||
| + | .overlap-button-text { | ||
| + | background-color: rgba(94, 94, 94, 0.5); | ||
| + | border-radius: 60px; | ||
| + | color: white; | ||
| + | font-size: 12px; | ||
} | } | ||
.firstword { | .firstword { | ||
| − | font-family: ' | + | font-family: 'objektiv-mk1' !important; |
font-size: 70px; | font-size: 70px; | ||
} | } | ||
| − | + | .titleimg { | |
| − | + | vertical-align: middle; | |
| − | + | width: 40%; | |
| − | + | } | |
| − | + | ||
p { | p { | ||
| − | + | font-family: 'objektiv-mk1' !important; | |
| − | + | margin-left: 10px !important; | |
| − | + | margin-right: 10px !important; | |
| − | + | font-size: small !important; | |
| − | + | } | |
h1 { | h1 { | ||
| − | + | font-size: 140%; | |
| − | + | } | |
.quote { | .quote { | ||
| − | font-family: ' | + | font-family: 'objektiv-mk1' !important; |
font-style: italic !important; | font-style: italic !important; | ||
font-size: 17px; | font-size: 17px; | ||
| Line 303: | Line 404: | ||
.quote-person { | .quote-person { | ||
width: 60% !important; | width: 60% !important; | ||
| − | font-family: ' | + | font-family: 'objektiv-mk1' !important; |
font-size: 12px; | font-size: 12px; | ||
text-align: right !important; | text-align: right !important; | ||
| Line 318: | Line 419: | ||
padding-left: 0px; | padding-left: 0px; | ||
padding-right: 0px; | padding-right: 0px; | ||
| + | } | ||
| + | |||
| + | .metabolic-pathway { | ||
| + | margin: auto; | ||
| + | background: honeydew; | ||
| + | width: 110%; | ||
| + | margin-left: -20px; | ||
| + | margin-right: -20px; | ||
} | } | ||
figcaption { | figcaption { | ||
| − | font-size: | + | font-size: 12px; |
| − | line-height: | + | line-height: 130%; |
| + | } | ||
| + | |||
| + | .reference-list { | ||
| + | font-family: 'objektiv-mk1'; | ||
| + | font-size: 12px; | ||
| + | text-align: left; | ||
| + | list-style-type: none; | ||
| + | line-height: 100%; | ||
| + | margin-bottom: 80px; | ||
| + | margin-right: -50px; | ||
| + | margin-left: -50px; | ||
} | } | ||
} | } | ||
| Line 338: | Line 458: | ||
<div id="page"> | <div id="page"> | ||
<center> | <center> | ||
| − | + | <br> | |
| + | <br> | ||
| − | + | <img class="titleimg" src="https://static.igem.org/mediawiki/2017/c/cf/Acetaminophen.png"> | |
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| + | <h1>ACETAMINOPHEN METABOLICS</h1> | ||
| + | |||
| + | <br> | ||
| + | |||
| + | <div class="text-container"> | ||
<div class="container"> | <div class="container"> | ||
<p><span class="quote">"Antipyretic drugs, by being analgesics, reduce not only the fever but also the pain."</span></p> | <p><span class="quote">"Antipyretic drugs, by being analgesics, reduce not only the fever but also the pain."</span></p> | ||
| Line 360: | Line 477: | ||
<br> | <br> | ||
| − | <div class="metabolic-pathway"> | + | <!-- <div class="container"> --> |
| − | + | <div class="metabolic-pathway"> | |
| − | </div> | + | <img src="https://static.igem.org/mediawiki/2017/c/ca/Acet-syn.png" style="width: 100%;"> |
| + | </div> | ||
| + | <!-- </div> --> | ||
| + | <br> | ||
<br> | <br> | ||
<br> | <br> | ||
| − | <div class="text-container"> | + | <!-- <div class="text-container"> --> |
| − | <div class="paragraph-left"> | + | <!-- <div class="paragraph-left"> --> |
| − | + | <p>We aim to genetically modify <i>S. elongatus</i> PCC 7942 to produce acetaminophen, a common mild anesthetic and antipyretic recognized by the WHO as an essential medicine<sup>[1]</sup>. However, in many countries with lower regulations and faulty policies regarding drug manufacturing, acetaminophen can be synthesized with lethal toxins that result in hundreds of deaths worldwide<sup>[23]</sup>. Acetaminophen is often used in conjunction with opioid pain medications postoperatively to enhance pain relief, thus reducing reliance upon opioid pharmaceuticals<sup>[24]</sup>.</p> | |
| − | </div> | + | <!-- </div> --> |
| − | </div> | + | <!-- </div> --> |
<!-- <div class="container"> | <!-- <div class="container"> | ||
| Line 377: | Line 497: | ||
<div class="col-md-8"> | <div class="col-md-8"> | ||
<figure> | <figure> | ||
| − | <img src="https://static.igem.org/mediawiki/2017/ | + | <img src="https://static.igem.org/mediawiki/2017/4/4d/Acetaminophensyn.png" style="width: 100%;"> |
| − | <figcaption style="font-family: ' | + | <figcaption style="font-family: 'objektiv-mk1'; font-style: italic; font-size: 13px;">Current synthetic biology approach to manufacturing acetaminophen in E.coli <sup>[25, 26]</sup>.Genes 4ABH and nhoA were inserted to synthesize the pathway in PCC 7942. The gene from A.bisporus, 4ABH, produces 4-aminophenol while the E. coli gene nhoA converts that 4-aminophenol to acetaminophen <sup>[25]</sup>.</figcaption> |
</figure> | </figure> | ||
</div> | </div> | ||
| Line 389: | Line 509: | ||
</div> --> | </div> --> | ||
| − | <div class=" | + | <div class="metabolic-pathway"> |
| − | <div class="row"> | + | <!-- <div class="row"> --> |
<figure> | <figure> | ||
| − | <img src="https://static.igem.org/mediawiki/2017/ | + | <img src="https://static.igem.org/mediawiki/2017/4/4d/Acetaminophensyn.png" style="width: 100%; padding: 20px"> |
<figcaption>Current synthetic biology approach to manufacturing acetaminophen in <span style="font-style: italic";>E. coli</span> <sup>[25, 26]</sup>. Genes <span style="font-style: italic";>4ABH</span> and <span style="font-style: italic";>nhoA</span> were inserted to synthesize the pathway in PCC 7942. The gene from <span style="font-style: italic";>A. bisporus, 4ABH</span>, produces 4-aminophenol while the <span style="font-style: italic";>E. coli</span> gene <span style="font-style: italic";>nhoA</span> converts that 4-aminophenol to acetaminophen <sup>[25]</sup>.</figcaption> | <figcaption>Current synthetic biology approach to manufacturing acetaminophen in <span style="font-style: italic";>E. coli</span> <sup>[25, 26]</sup>. Genes <span style="font-style: italic";>4ABH</span> and <span style="font-style: italic";>nhoA</span> were inserted to synthesize the pathway in PCC 7942. The gene from <span style="font-style: italic";>A. bisporus, 4ABH</span>, produces 4-aminophenol while the <span style="font-style: italic";>E. coli</span> gene <span style="font-style: italic";>nhoA</span> converts that 4-aminophenol to acetaminophen <sup>[25]</sup>.</figcaption> | ||
</figure> | </figure> | ||
| − | </div> | + | <!-- </div> --> |
</div> | </div> | ||
| Line 402: | Line 522: | ||
<br> | <br> | ||
<br> | <br> | ||
| − | <div class="text-container"> | + | <!-- <div class="text-container"> |
| − | <div class="paragraph-left"> | + | <div class="paragraph-left"> --> |
| − | + | <p>We are using a previously engineered pathway in <span style="font-style: italic";>E. coli</span> as a model of acetaminophen biosynthesis to enhance PCC 7942<sup>[26, 25]</sup>. The pathway converts chorismate, an abundant amino acid precursor of tryptophan, phenylalanine, and tyrosine, into acetaminophen with the addition ofthe <span style="font-style: italic";>4ABH</span> gene from <span style="font-style: italic";>A. bisporus</span>, an edible mushroom, and <span style="font-style: italic";>nhoA</span> from <span style="font-style: italic";>E. coli</span>. For more information on acetaminophen metabolics, check out <a href="https://2017.igem.org/Team:UCSC/Model">our modeling page!</a></p> | |
| − | </div> | + | <!-- </div> |
| − | </div> | + | </div> --> |
<br> | <br> | ||
<br> | <br> | ||
| + | <br> | ||
| + | |||
| + | <div class="container" style="width: 100%"> | ||
| + | <div class="row"> | ||
| + | <div class="col-md-4"> | ||
| + | <h3>P R O J E C T</h3> | ||
| + | <hr> | ||
| + | <a href="https://2017.igem.org/Team:UCSC/Project" class="proj-button"> | ||
| + | <img src="https://static.igem.org/mediawiki/2017/6/64/UCSCproject.png" class="proj-button-image-solo"> | ||
| + | <div class="proj-button-desc"> | ||
| + | <div class="overlap-button-text">HOMEPAGE</div> | ||
| + | </div> | ||
| + | </a> | ||
| + | </div> | ||
| + | |||
| + | <div class="col-md-8"> | ||
| + | <h3>Click here to learn more!</h3> | ||
| + | <hr> | ||
| + | <div class="row"> | ||
| + | <a href="https://2017.igem.org/Team:UCSC/B-12" class="proj-button"> | ||
| + | <img src="https://static.igem.org/mediawiki/2017/a/a2/B12_flask_button.png" class="proj-button-image"> | ||
| + | <div class="proj-button-desc"> | ||
| + | <div class="overlap-button-text">VITAMIN B<sub>12</sub></div> | ||
| + | </div> | ||
| + | </a> | ||
| + | |||
| + | <a href="https://2017.igem.org/Team:UCSC/Model" class="proj-button"> | ||
| + | <img src="https://static.igem.org/mediawiki/2017/b/be/Modeling_button.png" class="proj-button-image"> | ||
| + | <div class="proj-button-desc"> | ||
| + | <div class="overlap-button-text">MODELING</div> | ||
| + | </div> | ||
| + | </a> | ||
| + | |||
| + | <a href="https://2017.igem.org/Team:UCSC/Demonstrate" class="proj-button"> | ||
| + | <img src="https://static.igem.org/mediawiki/2017/a/ad/Resulticon.png" class="proj-button-image"> | ||
| + | <div class="proj-button-desc"> | ||
| + | <div class="overlap-button-text">RESULTS</div> | ||
| + | </div> | ||
| + | </a> | ||
| + | </div> | ||
| + | <div class="row"> | ||
| + | |||
| + | <a href="https://2017.igem.org/Team:UCSC/Target-Organism" class="proj-button"> | ||
| + | <img src="https://static.igem.org/mediawiki/2017/8/84/Spirulinaicon.png" class="proj-button-image"> | ||
| + | <div class="proj-button-desc"> | ||
| + | <div class="overlap-button-text">TARGET ORGANISM</div> | ||
| + | </div> | ||
| + | </a> | ||
| + | |||
| + | <a href="https://2017.igem.org/Team:UCSC/Part_Collection" class="proj-button"> | ||
| + | <img src="https://static.igem.org/mediawiki/2017/9/9c/Parts_icon.png" class="proj-button-image"> | ||
| + | <div class="proj-button-desc"> | ||
| + | <div class="overlap-button-text">PARTS</div> | ||
| + | </div> | ||
| + | </a> | ||
| + | </div> | ||
| + | </div> | ||
| + | </div> | ||
<br> | <br> | ||
| Line 415: | Line 593: | ||
<div class="reference-list"> | <div class="reference-list"> | ||
<hr> | <hr> | ||
| − | <li>[1] World Health Organization, ed.,<span class="reference-italic">The Selection and Use of Essential Medicines: report of | + | <li>[1] World Health Organization, ed.,<span class="reference-italic">The Selection and Use of Essential Medicines: report of the WHO Expert Committee, 2007 ; (including the 15th model list of essential medicines).</span> No. 946in WHO Technical Report Series, Geneva: World Health Organization, 2007. OCLC: 254437808.</li> |
<li>[23] P. N. Newton, M. D. Green, and F. M. Fern ́andez, “Impact of poor-quality medicines in the‘developing’ world,”<span class="reference-italic">Trends in Pharmacological Sciences</span>, vol. 31, pp. 99–101, Mar. 2010.</li> | <li>[23] P. N. Newton, M. D. Green, and F. M. Fern ́andez, “Impact of poor-quality medicines in the‘developing’ world,”<span class="reference-italic">Trends in Pharmacological Sciences</span>, vol. 31, pp. 99–101, Mar. 2010.</li> | ||
<li>[24] S. A. Schug, D. A. Sidebotham, M. McGuinnety, J. Thomas, and L. Fox, “Acetaminophen as anadjunct to morphine by patient-controlled analgesia in the management of acute postoperativepain,”<span class="reference-italic">Anesthesia and Analgesia</span>, vol. 87, pp. 368–372, Aug. 1998.</li> | <li>[24] S. A. Schug, D. A. Sidebotham, M. McGuinnety, J. Thomas, and L. Fox, “Acetaminophen as anadjunct to morphine by patient-controlled analgesia in the management of acute postoperativepain,”<span class="reference-italic">Anesthesia and Analgesia</span>, vol. 87, pp. 368–372, Aug. 1998.</li> | ||
| Line 422: | Line 600: | ||
</div> | </div> | ||
</div> | </div> | ||
| + | |||
| + | <br> | ||
| + | <br> | ||
</center> | </center> | ||
</div> | </div> | ||
| + | </center> | ||
</body> | </body> | ||
</html> | </html> | ||
| − | |||
{{UCSC-Footer}} | {{UCSC-Footer}} | ||
Latest revision as of 01:44, 2 November 2017
ACETAMINOPHEN METABOLICS
"Antipyretic drugs, by being analgesics, reduce not only the fever but also the pain."
~Clinical Manual of Fever in Children
We aim to genetically modify S. elongatus PCC 7942 to produce acetaminophen, a common mild anesthetic and antipyretic recognized by the WHO as an essential medicine[1]. However, in many countries with lower regulations and faulty policies regarding drug manufacturing, acetaminophen can be synthesized with lethal toxins that result in hundreds of deaths worldwide[23]. Acetaminophen is often used in conjunction with opioid pain medications postoperatively to enhance pain relief, thus reducing reliance upon opioid pharmaceuticals[24].
We are using a previously engineered pathway in E. coli as a model of acetaminophen biosynthesis to enhance PCC 7942[26, 25]. The pathway converts chorismate, an abundant amino acid precursor of tryptophan, phenylalanine, and tyrosine, into acetaminophen with the addition ofthe 4ABH gene from A. bisporus, an edible mushroom, and nhoA from E. coli. For more information on acetaminophen metabolics, check out our modeling page!
